Background
This study aimed to determine the prognostic survival impact of preoperative carbohydrate CA19-9 levels in resectable cholangiocarcinoma.
Methods
PubMed, Web of Science, Cochrane, and Embase databases were searched for articles published through April 28, 2023. The relationship between preoperative serum carbohydrate antigen 19-9 and the prognosis of patients with resectable cholangiocarcinoma was analyzed. Heterogeneity between studies was assessed by means of the I
2
statistic. We also performed subgroup analyses based on anatomical site of the tumor, geographic region, time of occurrence, and different levels of CA19-9. A random effects model was performed to express effect sizes as Hazard Ratio (HR) with 95% confidence intervals (CIs).
Results
A total of 60 original studies were eligible for inclusion, with a total of 15,031 patients with all sites, including 9014 males. The overall Hazard Ratio for all studies was 1.90 (95% CI 1.74–2.07,
p
< 0.001,
Z
= 14.59). Publication bias was suggested by the Begg’s test (
p
= 0.014 < 0.05), and the overall HR was 1.66 (95% CI 1.53–1.80,
p
< 0.001,
Z
= 12.027) after the trim-and-filling method. Subgroup analyses showed that intrahepatic cholangiocarcinoma (HR = 2.00, 95% CI 1.79–2.23), extrahepatic cholangiocarcinoma (HR = 1.65, 95% CI 1.49–1.82), hilar cholangiocarcinoma (HR = 1. 82, 95% CI 1.60–2.07), and distal cholangiocarcinoma (HR = 1.66, 95% CI 1.27–2.15) were predicted to be linked with prognosis. Elevated CA19-9 levels were associated with an increased risk of death.
Conclusions
This meta-analysis showed that elevated CA19-9 levels were correlated with a poor prognosis in cholangiocarcinoma. In future, more distal and hilar cholangiocarcinoma should be included in statistical studies to improve the accuracy of our conclusions.
Supplementary Information
The online version contains supplementary material available at 10.1007/s12672-024-01683-w.